[Treatment strategies for patients with atrial fibrillation and chronic heart failure]

S N Tereshchenko1,2, T M Uskach1,2

  • 1National Medical Research Center of Cardiology.

Terapevticheskii Arkhiv
|October 26, 2022
PubMed

Insights

Atrial fibrillation (AF) and chronic heart failure (CHF) often coexist, worsening patient outcomes. This review details their prevalence, prognosis, and optimal management strategies, focusing on rhythm control and anticoagulation safety.

Area of Science:

  • Cardiology
  • Internal Medicine

Context:

  • Atrial fibrillation (AF) and chronic heart failure (CHF) are prevalent cardiovascular conditions.
  • These conditions frequently coexist, creating a complex clinical scenario with significant morbidity and mortality.
  • The bidirectional relationship between AF and CHF necessitates tailored treatment approaches.

Purpose:

  • To review the prevalence and prognostic implications of concurrent AF and CHF.
  • To discuss current management strategies, including rhythm control and anticoagulation.
  • To highlight the importance of safety, particularly bleeding risk, in anticoagulant therapy for these patients.

Summary:

  • This article synthesizes data from meta-analyses on managing patients with both AF and CHF.
  • It examines rhythm control strategies in AF with concomitant CHF, referencing recent studies and clinical guidelines.
  • Key aspects of anticoagulant therapy, emphasizing safety and bleeding risk, are detailed.

Impact:

  • Provides clinicians with updated insights into the complex interplay of AF and CHF.
  • Informs treatment decisions regarding rhythm control and anticoagulation in this high-risk patient population.
  • Underscores the critical need for balancing therapeutic efficacy with safety to improve patient outcomes.

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
487
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
27
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
415
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
27